
WHAT IS CLAIMED IS:

1. A compound of Formula 1,



1

or a pharmaceutically acceptable salt thereof in which:

X^1 is selected from N and CR^1;

X^2 is selected from N and CR^2;

X^3 is selected from N and CR^3; and

X^4 is selected from N and CR^4, provided no more than two of X^1, X^2, X^3, and X^4 are N;

X^{13} is NR^{13} and X^{14} is $CR^{15}R^{16}$ or X^{13} is CH_2 and X^{14} is NR^{14};

L is selected from NR^8 and O;

r is selected from 0 and 1;

s is selected from 0 and 1;

R^1, R^2, and R^3 are each independently selected from

(a) hydrogen, halo, hydroxy, and cyano; and

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo;

R^4 is selected from

(a) hydrogen, halo, hydroxy, and cyano; and

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo;

R^5 is selected from

(a) hydrogen, halo, hydroxy, and cyano; and

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo, oxo, and phenyl which is substituted with 0 to 3 optional substituents independently selected from halo; or

R^4 and R^5, together with the carbon atoms to which they are attached, form a cyclopent-1-en-1,2-diyl or a furan-2,3-diyl;

R^6 and R^7 are each independently selected from halo and C_{1-3} alkyl, or R^6 and R^7, together with the carbon atom to which they are attached, form a C_{3-4} cycloalkan-1,1-diyl;

R^8 is selected from H and C_{1-4} alkyl;

R^9 and R^{10} are each independently selected from

(a) hydrogen, halo, hydroxy, and cyano;

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; and

(c) phenyl and C_{1-5} heteroaryl, each substituted with 0 to 3 optional substituents independently selected from halo, C_{1-4} alkyl, and C_{1-4} alkoxy, wherein the C_{1-5} heteroaryl substituent is a monocyclic ring with 5 to 6 ring members in which 1 to 4 ring members are heteroatoms, each of the heteroatoms independently selected from N, O, and S, provided no more than one of the ring members is O or S, and wherein the C_{1-4} alkyl and C_{1-4} alkoxy optional substituents on phenyl and C_{1-5} heteroaryl are each independently substituted with 0 to 3 optional substituents independently selected from halo; or

R^9 and R^{10}, together with the carbon atom to which they are attached, form a C_{3-4} cycloalkan-1,1-diyl;

R^{11} and R^{12} are each independently selected from

(a) hydrogen, halo, hydroxy, and cyano; and

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; or

R^{11} and R^{12}, together with the carbon atom to which they are attached, form a C_{3-4} cycloalkan-1,1-diyl;

R^{13} and R^{14} are each independently selected from

(a) hydrogen; and

(b) C_{1-4} alkyl, which is substituted with 0 to 3 optional substituents independently selected from cyano, oxo, and phenyl which is substituted with 0 to 3 optional substituents independently selected from halo; and

R^{15} and R^{16} are each independently selected from

(a) hydrogen, halo, hydroxy, and cyano; and

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; or

R^{15} and R^{16}, together with the carbon atom to which they are attached, form a C_{3-4} cycloalkan-1,1-diyl.

2. The compound or pharmaceutically acceptable salt according to claim 1, wherein X^1 is CR^1, X^2 is CR^2, X^3 is CR^3, and X^4 is CR^4.

3. The compound or pharmaceutically acceptable salt according to claim 2, wherein R^1, R^2, R^3, and R^4 are each independently selected from

(a) hydrogen, halo, and cyano; and

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

4. The compound or pharmaceutically acceptable salt according to claim 2, wherein R^1, R^2, R^3, and R^4 are each independently selected from

(a) hydrogen, halo, and cyano; and

(b) C_{1-4} alkyl and C_{3-6} cycloalkyl, each substituted with 0 to 3 optional substituents independently selected from halo.

5. The compound or pharmaceutically acceptable salt according to claim 2, wherein R^1, R^2, R^3, and R^4 are each independently selected from

(a) hydrogen, halo, and cyano; and

(b) methyl and cyclopropyl, each substituted with 0 to 3 optional substituents independently selected from halo.

6. The compound or pharmaceutically acceptable salt according to claim 2, wherein R^1, R^2, R^3, and R^4 are each independently selected from hydrogen, halo, cyano, methyl, trifluoromethyl, and cyclopropyl.

7. The compound or pharmaceutically acceptable salt according to claim 1, wherein X^1 is N, X^2 is CR^2, X^3 is CR^3, and X^4 is CR^4.

8. The compound or pharmaceutically acceptable salt according to claim 7, wherein R^2, R^3, and R^4 are each independently selected from

(a) hydrogen, halo, and cyano; and

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

9. The compound or pharmaceutically acceptable salt according to claim 7, wherein R^2, R^3, and R^4 are each independently selected from

(a) hydrogen, halo, and cyano; and

(b) C_{1-4} alkyl and C_{3-6} cycloalkyl, each substituted with 0 to 3 optional substituents independently selected from halo.

10. The compound or pharmaceutically acceptable salt according to claim 7, wherein R^2, R^3, and R^4 are each independently selected from

(a) hydrogen, halo, and cyano; and

(b) methyl and cyclopropyl, each substituted with 0 to 3 optional substituents independently selected from halo.

11. The compound or pharmaceutically acceptable salt according to claim 7, wherein R^2, R^3, and R^4 are each independently selected from hydrogen, halo, cyano, methyl, trifluoromethyl, and cyclopropyl.

12. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 11, wherein R^5 is selected from

(a) hydrogen, halo, hydroxy, and cyano; and

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo, oxo, and phenyl which is substituted with 0 to 3 optional substituents independently selected from halo.

13. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 11, wherein R^5 is selected from

(a) halo and cyano; and

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

14. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 11, wherein R^5 is selected from

(a) fluoro, chloro, bromo, and cyano; and

(b) methyl, ethyl, cyclopropyl, methoxy, and ethoxy, each substituted with 0 to 3 optional substituents independently selected from fluoro.

15. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 14, wherein R^6 and R^7 are each independently selected from fluoro and methyl or together with the carbon atom to which they are attached form a cyclopropan-1,1-diyl or a cyclobutan-1,1-diyl.

16. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 14, wherein each of R^6 and R^7 is methyl.

17. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 16, wherein L is NR^8.

18. The compound or pharmaceutically acceptable salt according to claim 17, wherein R^8 is selected from hydrogen and methyl.

19. The compound or pharmaceutically acceptable salt according to claim 17, wherein R^8 is hydrogen.

20. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 19, wherein R^9 and R^{10} are each independently selected from

(a) hydrogen, halo, hydroxy, and cyano;

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; and

(c) phenyl and C_{1-5} heteroaryl, each substituted with 0 to 3 optional substituents independently selected from halo, C_{1-4} alkyl, and C_{1-4} alkoxy, wherein the C_{1-5} heteroaryl substituent is a monocyclic ring with 5 to 6 ring members in which 1 to 4 ring members are heteroatoms, each of the heteroatoms independently selected from N, O, and S, provided no more than one of the ring members is O or S, and wherein the C_{1-4} alkyl and C_{1-4} alkoxy optional substituents on phenyl and C_{1-5} heteroaryl are each independently substituted with 0 to 3 optional substituents independently selected from halo.

21. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 19, wherein R^9 and R^{10} are each independently selected from

(a) hydrogen and halo;

(b) C_{1-4} alkyl and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; and

(c) phenyl and C_{1-5} heteroaryl, each substituted with 0 to 3 optional substituents independently selected from halo and C_{1-4} alkyl, wherein the C_{1-5} heteroaryl substituent is a monocyclic ring with 5 to 6 ring members in which 1 or 2 ring members are heteroatoms, each of the heteroatoms being N, and wherein the C_{1-4} alkyl optional substituents on phenyl and C_{1-5} heteroaryl are each independently substituted with 0 to 3 optional substituents independently selected from halo.

22. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 19, wherein R^9 and R^{10} are each independently selected from

(a) hydrogen and halo;

(b) C_{1-4} alkyl and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo; and

(c) phenyl, pyridinyl, and pyrazolyl, each substituted with 0 to 3 optional substituents independently selected from halo and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo.

23. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 19, wherein R^9 and R^{10} are selected from hydrogen, halo, and C_{1-4} alkyl.

24. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 23, wherein R^{11} and R^{12} are each independently selected from

(a) hydrogen, halo, hydroxy, and cyano; and

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

25. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 23, wherein R^{11} and R^{12} are each independently selected from hydrogen and C_{1-4} alkyl.

26. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 25, wherein X^{13} is NR^{13} and X^{14} is $CR^{15}R^{16}$.

27. The compound or pharmaceutically acceptable salt according to claim 26, wherein R^{13} is selected from

(a) hydrogen; and

(b) C_{1-4} alkyl, which is substituted with 0 to 3 optional substituents independently selected from cyano, oxo, and phenyl which is substituted with 0 to 3 optional substituents independently selected from halo.

28. The compound or pharmaceutically acceptable salt according to claim 26, wherein R^{13} is selected from hydrogen and methyl.

29. The compound or pharmaceutically acceptable salt according to claim 26, wherein R^{13} is methyl.

30. The compound or pharmaceutically acceptable salt according to any one of claims 26 to 29, wherein R^{15} and R^{16} are each independently selected from

(a) hydrogen, halo, hydroxy, and cyano; and

(b) C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{1-4} alkoxy, each substituted with 0 to 3 optional substituents independently selected from halo.

31. The compound or pharmaceutically acceptable salt according to any one of claims 26 to 29, wherein R^{15} and R^{16} are each independently selected from hydrogen and C_{1-4} alkyl which is substituted with 0 to 3 optional substituents independently selected from halo.

32. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 31, wherein r is 0.

33. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 32, wherein s is 0.

34. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 32, wherein s is 1.

35. The compound according to claim 1, which is selected from the following compounds:

2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)-3-((3-methylpyridin-2-yl)oxy)propanamide;

2,2-dimethyl-3-((3-methylpyridin-2-yl)oxy)-*N*-(1-methylpyrrolidin-3-yl)propanamide;

3-((3-cyanopyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

(*R*)-3-((5-cyclopropylpyrimidin-4-yl)oxy)-2,2-dimethyl-*N*-(1-methylpyrrolidin-3-yl)propanamide;

3-((5-cyclopropylpyrimidin-4-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-((3-cyclopropyl-5-methylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

(*R*)-3-((3-cyclopropyl-5-methylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpyrrolidin-3-yl)propanamide;

3-((5-cyclopropyl-3-methylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-((3-cyclopropyl-6-methylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

(*R*)-3-((3-cyclopropyl-6-methylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpyrrolidin-3-yl)propanamide;

trans-*N*-(1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

cis-*N*-(1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-*N*-(1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

cis-*N*-(1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

trans-*N*-(4-isopropyl-1-methylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-*N*-(4-isopropyl-1-methylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

trans-*N*-(1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-methylpyridin-2-yl)oxy)propanamide;

trans-2,2-dimethyl-*N*-(1-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)pyrrolidin-3-yl)-3-((3-methylpyridin-2-yl)oxy)propanamide;

trans-2,2-dimethyl-*N*-(1-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)pyrrolidin-3-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-3-((3-cyclopropylpyridin-2-yl)oxy)-*N*-(1,3-dimethylpiperidin-4-yl)-2,2-dimethylpropanamide;

cis-3-((3-cyclopropylpyridin-2-yl)oxy)-*N*-(1,3-dimethylpiperidin-4-yl)-2,2-dimethylpropanamide;

trans-3-((3-cyclopropylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)pyrrolidin-3-yl)propanamide;

trans-*N*-(4-(1,3-dimethyl-1*H*-pyrazol-4-yl)-1-methylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-methylpyridin-2-yl)oxy)propanamide;

trans-3-((3-cyclopropylpyridin-2-yl)oxy)-*N*-(4-(1,3-dimethyl-1*H*-pyrazol-4-yl)-1-methylpyrrolidin-3-yl)-2,2-dimethylpropanamide;

trans-*N*-(4-(1,3-dimethyl-1*H*-pyrazol-4-yl)-1-methylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-*N*-(4-(1,5-dimethyl-1*H*-pyrazol-4-yl)-1-methylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-methylpyridin-2-yl)oxy)propanamide;

trans-3-((3-cyclopropylpyridin-2-yl)oxy)-*N*-(4-(1,5-dimethyl-1*H*-pyrazol-4-yl)-1-methylpyrrolidin-3-yl)-2,2-dimethylpropanamide;

trans-*N*-(4-(1,5-dimethyl-1*H*-pyrazol-4-yl)-1-methylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-*N*-(4-(1,3-dimethyl-1*H*-pyrazol-4-yl)-1-methylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

trans-*N*-(4-(1,5-dimethyl-1*H*-pyrazol-4-yl)-1-methylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

trans-*N*-(1,3-dimethylpiperidin-4-yl)-3-((3,5-dimethylpyridin-2-yl)oxy)-2,2-dimethylpropanamide;

cis-*N*-(1,3-dimethylpiperidin-4-yl)-3-((3,5-dimethylpyridin-2-yl)oxy)-2,2-dimethylpropanamide;

trans-*N*-(3-isopropyl-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

cis-*N*-(3-isopropyl-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)-*N*-(1,5,5-trimethylpyrrolidin-3-yl)propanamide;

(*R*)-2,2-dimethyl-*N*-((1-methylpyrrolidin-3-yl)methyl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

(*S*)-2,2-dimethyl-N-((1-methylpyrrolidin-3-yl)methyl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

3-((3-chloropyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-((3-fluoropyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-((3,5-difluoropyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)-3-((4-(trifluoromethyl)pyridin-3-yl)oxy)propanamide;

2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)-3-((3-(trifluoromethyl)pyridin-4-yl)oxy)propanamide;

3-((4-chloro-3-fluoropyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-((3-chloro-5-fluoropyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-((6-chloro-2-methylpyridin-3-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-((3-cyclopropylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-((5-chloro-3-methylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-((3-methoxypyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)-3-((3-methylpyridin-4-yl)oxy)propanamide;

3-((5-cyano-3-methylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)-3-((2-(trifluoromethyl)pyridin-3-yl)oxy)propanamide;

(*R*)-3-((3-cyclopropylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpyrrolidin-3-yl)propanamide;

3-((3-ethoxypyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

trans-*N*-(4-(4-chlorophenyl)-1-methylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-methylpyridin-2-yl)oxy)propanamide;

trans-*N*-(4-(4-chlorophenyl)-1-methylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-2,2-dimethyl-*N*-(1-methyl-4-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)-3-((3-methylpyridin-2-yl)oxy)propanamide;

trans-3-((3-cyclopropylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methyl-4-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)propanamide;

trans-2,2-dimethyl-*N*-(1-methyl-4-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-2,2-dimethyl-*N*-(1-methyl-4-(6-methylpyridin-3-yl)pyrrolidin-3-yl)-3-((3-methylpyridin-2-yl)oxy)propanamide;

trans-3-((3-cyclopropylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methyl-4-(6-methylpyridin-3-yl)pyrrolidin-3-yl)propanamide;

trans-2,2-dimethyl-*N*-(1-methyl-4-(6-methylpyridin-3-yl)pyrrolidin-3-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-(1-methylpiperidin-4-yl)-1-(((3-methylpyridin-2-yl)oxy)methyl)cyclopropane-1-carboxamide;

2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)-3-(2-(trifluoromethyl)phenoxy)propanamide;

(*R*)-2,2-dimethyl-*N*-(1-methylpyrrolidin-3-yl)-3-(2-(trifluoromethyl)phenoxy)propanamide;

3-(2-chlorophenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-(2-bromophenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

(*R*)-3-(2-chlorophenoxy)-2,2-dimethyl-*N*-(1-methylpyrrolidin-3-yl)propanamide;

(*R*)-3-(2-bromophenoxy)-2,2-dimethyl-*N*-(1-methylpyrrolidin-3-yl)propanamide;

3-(2-cyclopropylphenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

(*R*)-3-(2-cyclopropylphenoxy)-2,2,-dimethyl-*N*-(1-methylpyrrolidin-3-yl)propanamide;

3-(2-ethylphenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-(4-cyano-2-(trifluoromethyl)phenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)-3-phenoxypropanamide;

3-(3-cyano-2-methylphenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;
2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)-3-(o-tolyloxy)propanamide;
3-(2-cyano-6-methylphenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;
3-(2-ethoxyphenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;
3-((2,3-dihydro-1*H*-inden-4-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;
3-((3-cyclopropylpyrazin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;
1-((2-chlorophenoxy)methyl)-*N*-(1-methylpiperidin-4-yl)cyclopropane-1-carboxamide;
3-((3-chloro-5-methylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;
3-((3,6-dimethylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;
3-((3,5-dimethylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;
3-((3-ethylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;
(*R*)-3-((3-ethylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpyrrolidin-3-yl)propanamide;
3-((3-ethylpyrazin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;
3-((3,4-dimethylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;
1-(((3-cyclopropylpyridin-2-yl)oxy)methyl)-*N*-(1-methylpiperidin-4-yl)cyclobutane-1-carboxamide;
3-((3-(difluoromethyl)pyridin-2-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;
2,2-dimethyl-3-((3-methyl-5-(trifluoromethyl)pyridin-2-yl)oxy)-N-(1-methylpiperidin-4-yl)propanamide;
2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;
trans-*N*-(4-(4-chlorophenyl)-1-methylpyrrolidin-3-yl)-3-((3,5-dimethylpyridin-2-yl)oxy)-2,2-dimethylpropanamide;

trans-*N*-(4-(4-chlorophenyl)-1-methylpyrrolidin-3-yl)-3-((3-cyclopropylpyridin-2-yl)oxy)-2,2-dimethylpropanamide;

trans-*N*-(4-ethoxy-1-methylpyrrolidin-3-yl)-3-(2-ethylphenoxy)-2,2-dimethylpropanamide;

trans-3-(2-ethylphenoxy)-*N*-(4-methoxy-1-methylpyrrolidin-3-yl)-2,2-dimethylpropanamide;

3-(2-ethylphenoxy)-2,2-dimethyl-*N*-(1-methyl-4-phenylpyrrolidin-3-yl)propanamide;

3-((6-chloro-4-(trifluoromethyl)pyridazin-3-yl)oxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-(furo[3,2-*c*]pyridin-4-yloxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-((5-bromo-3-(trifluoromethyl)pyridin-2-yl)oxy)-2,2-dimethyl-N-(1-methylpiperidin-4-yl)propanamide;

2,2-dimethyl-3-((5-methyl-3-(trifluoromethyl)pyridin-2-yl)oxy)-*N*-(1-methylpiperidin-4-yl)propanamide;

2,2-dimethyl-N-(1-methylpiperidin-4-yl)-3-(2-(trifluoromethoxy)phenoxy)propanamide;

trans-*N*-(1-(cyanomethyl)-4-(6-methylpyridin-3-yl)pyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-(1-(2-(4-chlorophenyl)-2-oxoethyl)piperidin-4-yl)-3-(2-ethylphenoxy)-2,2-dimethylpropanamide;

N-((3*S*,4*S*)-1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-((3*R*,4*R*)-1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-((3*S*,4*S*)-1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

N-((3*R*,4*R*)-1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

trans-*N*-(1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-*N*-(3-ethyl-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

cis-*N*-(3-ethyl-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)-*N*-(1,3,3-trimethylpiperidin-4-yl)propanamide;

N-(3-fluoro-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(5-methyl-5-azaspiro[2.5]octan-8-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-(*trans*-3-ethyl-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

N-(*cis*-3-ethyl-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

N-((3*S*,4*S*)-3-fluoro-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-(3,3-difluoro-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(5-methyl-5-azaspiro[2.5]octan-8-yl)-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

N-(3-chloro-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-((3*S*,4*S*)-3-fluoro-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-methylpyridin-2-yl)oxy)propanamide;

3-((3,5-dimethylpyridin-2-yl)oxy)-*N*-((3*S*,4*S*)-3-fluoro-1-methylpiperidin-4-yl)-2,2-dimethylpropanamide;

3-((3-cyclopropylpyridin-2-yl)oxy)-N-((3S,4S)-3-fluoro-1-methylpiperidin-4-yl)-2,2-dimethylpropanamide;

N-((3*S*,4*S*)-3-fluoro-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

trans-*N*-(3-(1-(difluoromethyl)-1*H*-pyrazol-4-yl)-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-*N*-(3-(1-(difluoromethyl)-1*H*-pyrazol-4-yl)-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

trans-*N*-(3-ethyl-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-methylpyridin-2-yl)oxy)propanamide;

trans-3-((3,5-dimethylpyridin-2-yl)oxy)-*N*-(3-ethyl-1-methylpiperidin-4-yl)-2,2-dimethylpropanamide;

cis-*N*-(1,2-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-*N*-(4-fluoropyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-(4,4-difluoropyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide ;

2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)-*N*-(1,2,2-trimethylpiperidin-4-yl)propanamide;

trans-*N*-(1,5-dimethylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

cis-*N*-(1,5-dimethylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-*N*-(1,2-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

cis-*N*-(1,2-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

N-(2-ethyl-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(5-methyl-5-azaspiro[2.4]heptan-7-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-*N*-(1,2-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-((3*R*,4*R*)-1,3-dimethylpiperidin-4-yl)-3-((3,5-dimethylpyridin-2-yl)oxy)-2,2-dimethylpropanamide;

N-((3*S*,4*S*)-1,3-dimethylpiperidin-4-yl)-3-((3,5-dimethylpyridin-2-yl)oxy)-2,2-dimethylpropanamide;

N-((3*R*,4*R*)-1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-methylpyridin-2-yl)oxy)propanamide;

N-((3*S*,4*S*)-1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-methylpyridin-2-yl)oxy)propanamide;

N-((3*R*,4*R*)-3-ethyl-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-((3*S*,4*S*)-3-ethyl-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-(2-ethyl-1-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

3-((3-cyclopropylpyridin-2-yl)oxy)-*N*-((2*R*,4*R*)-1,2-dimethylpiperidin-4-yl)-2,2-dimethylpropanamide;

(*R*)-2,2-dimethyl-*N*-(5-methyl-5-azaspiro[2.4]heptan-7-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-*N*-(2-ethyl-1-methylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

(*R*)-2,2-dimethyl-*N*-(5-methyl-5-azaspiro[2.4]heptan-7-yl)-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(5-methyl-5-azaspiro[3.4]octan-8-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-((2*S*,4*S*)-1,2-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

(*R*)-2,2-dimethyl-*N*-(5-methyl-5-azaspiro[2.4]heptan-7-yl)-3-((3-methylpyridin-2-yl)oxy)propanamide;

(*R*)-3-((3,5-dimethylpyridin-2-yl)oxy)-2,2-dimethyl-*N*-(5-methyl-5-azaspiro[2.4]heptan-7-yl)propanamide;

N,2,2-trimethyl-*N*-(*trans*-3-(*o*-tolyl)piperidin-4-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N,2,2-trimethyl-*N*-(*cis*-3-(*o*-tolyl)piperidin-4-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(*trans*-3-(*o*-tolyl)piperidin-4-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-((*3S,4S*)-3-fluoropiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-(3,3-difluoropiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-((*3S,4S*)-3-fluoropiperidin-4-yl)-*N*,2,2-trimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(*trans*-1-methyl-3-(*o*-tolyl)piperidin-4-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-*N*,2,2-trimethyl-*N*-(3-phenylpiperidin-4-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(*cis*-1-methyl-3-phenylpiperidin-4-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(*trans*-1-methyl-3-phenylpiperidin-4-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-(*trans*-1,4-dimethylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(*cis*-1-methyl-3-phenylpiperidin-4-yl)-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(*trans*-1-methyl-3-phenylpiperidin-4-yl)-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

trans-3-(*o*-tolyl)piperidin-4-yl 2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanoate;

2,2-dimethyl-*N*-(*trans*-1-methyl-4-(1-methyl-1H-pyrazol-4-yl)piperidin-3-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-3-(2-methylpyridin-3-yl)piperidin-4-yl 2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanoate;

trans-3-phenylpiperidin-4-yl 2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanoate;

N,2,2-trimethyl-*N*-(*trans* -3-(2-methylpyridin-3-yl)piperidin-4-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

(*S*)-2,2-dimethyl-*N*-(5-methyl-5-azaspiro[2.4]heptan-7-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(4-methyl-4-azaspiro[2.5]octan-7-yl)-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

2,2-dimethyl-*N*-(4-methyl-4-azaspiro[2.5]octan-7-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-((2*R*,4*R*)-1,2-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-((2*R*,4*S*)-1,2-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-((2*S*,4*S*)-1,2-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

N-((2*R*,4*R*)-1,2-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

N-(*trans*-1,4-dimethylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

3-((3-cyclopropylpyridin-2-yl)oxy)-*N*-(*trans*-1,4-dimethylpyrrolidin-3-yl)-2,2-dimethylpropanamide;

N-(*trans*-1,4-dimethylpyrrolidin-3-yl)-2,2-dimethyl-3-((3-methylpyridin-2-yl)oxy)propanamide;

3-((3,5-dimethylpyridin-2-yl)oxy)-*N*-(*trans*-1,4-dimethylpyrrolidin-3-yl)-2,2-dimethylpropanamide;

trans-*N*-(1-(cyanomethyl)-3-methylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

3-((3-(chlorodifluoromethoxy)pyridin-2-yl)oxy)-*N*-((3*S*,4*S*)-1,3-dimethylpiperidin-4-yl)-2,2-dimethylpropanamide;

trans-3-(2-chlorophenoxy)-*N*-(1,3-dimethylpiperidin-4-yl)-2,2-dimethylpropanamide;

3-(2-chlorophenoxy)-*N*-((3*S*,4*S*)-3-fluoropiperidin-4-yl)-2,2-dimethylpropanamide;

3-(2-chlorophenoxy)-*N*-((3*S*,4*S*)-3-fluoro-1-methylpiperidin-4-yl)-2,2-dimethylpropanamide;

trans-*N*-(1,3-dimethylpiperidin-4-yl)-2,2-difluoro-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide ;

3-(2-chlorophenoxy)-2,2-dimethyl-*N*-((3*S*,4*S*)-3-methylpiperidin-4-yl)propanamide;

cis-*N*-(1,2-dimethylpiperidin-4-yl)-2,2-difluoro-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

trans-3-((3-cyclopropylpyridin-2-yl)oxy)-*N*-(1,3-dimethylpiperidin-4-yl)-2,2-difluoropropanamide;

3-(2-chlorophenoxy)-*N*-((3*S*,4*S*)-1,3-dimethylpiperidin-4-yl)-2,2-dimethylpropanamide;

3-((3-cyclopropylpyridin-2-yl)oxy)-*N*-((2*R*,4*R*)-1,2-dimethylpiperidin-4-yl)-2,2-difluoropropanamide;

3-(2-fluorophenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-(2-fluorophenoxy)-2,2-dimethyl-*N*-((3*S*,4*S*)-3-methylpiperidin-4-yl)propanamide;

2,2-difluoro-*N*-((3*S*,4*S*)-3-fluoropiperidin-4-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

3-((3-cyclopropylpyridin-2-yl)oxy)-2,2-difluoro-*N*-((3*S*,4*S*)-3-fluoropiperidin-4-yl)propanamide;

N-(*trans*-1,3-dimethylpiperidin-4-yl)-2,2-difluoro-3-((3-methylpyridin-2-yl)oxy)propanamide;

N-(*trans*-1,3-dimethylpiperidin-4-yl)-2,2-difluoro-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

2,2-difluoro-*N*-((3*S*,4*S*)-3-fluoropiperidin-4-yl)-3-((3-methylpyridin-2-yl)oxy)propanamide;

N-((3*S*,4*S*)-1,3-dimethylpiperidin-4-yl)-3-(2-fluorophenoxy)-2,2-dimethylpropanamide;

3-(3-fluorophenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

3-(4-fluorophenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

N-((2*R*,4*R*)-1,2-dimethylpiperidin-4-yl)-2,2-difluoro-3-((3-methylpyridin-2-yl)oxy)propanamide;

N-((2*R*,4*R*)-1,2-dimethylpiperidin-4-yl)-2,2-difluoro-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

2,2-difluoro-*N*-((3*S*,4*S*)-3-fluoropiperidin-4-yl)-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

2,2-difluoro-*N*-((3*S*,4*S*)-3-methylpiperidin-4-yl)-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;

3-((3-cyclopropylpyridin-2-yl)oxy)-2,2-difluoro-*N*-((3*S*,4*S*)-3-methylpiperidin-4-yl)propanamide;

2,2-difluoro-*N*-((3*S*,4*S*)-3-methylpiperidin-4-yl)-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

3-((3-cyclopropylpyridin-2-yl)oxy)-2,2-difluoro-*N*-((2*R*,4*R*)-2-methylpiperidin-4-yl)propanamide;

2,2-difluoro-*N*-((2*R*,4*R*)-2-methylpiperidin-4-yl)-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide;

3-(2-chlorophenoxy)-2,2-dimethyl-*N*-(piperidin-4-yl)propanamide;

3-((3,5-dimethylpyridin-2-yl)oxy)-*N*-((3*R*,4*R*)-3-fluoropiperidin-4-yl)-2,2-dimethylpropanamide;

3-(2-chlorophenoxy)-2,2-difluoro-*N*-(1-methylpiperidin-4-yl)propanamide;

3-(2-chlorophenoxy)-2,2-difluoro-*N*-((3*S*,4*S*)-3-methylpiperidin-4-yl)propanamide;

3-(4-chlorophenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide;

N-((2*R*,4*R*)-1,2-dimethylpiperidin-4-yl)-3-((3,5-dimethylpyridin-2-yl)oxy)-2,2-dimethylpropanamide; and

a pharmaceutically acceptable salt of any one of the aforementioned compounds.

36. The compound according to claim 1, which is 3-(2-chlorophenoxy)-2,2-dimethyl-*N*-(1-methylpiperidin-4-yl)propanamide or a pharmaceutically acceptable salt thereof.

37. The compound according to claim 1, which is *N*-((3*S*,4*S*)-1,3-dimethylpiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethoxy)pyridin-2-yl)oxy)propanamide or a pharmaceutically acceptable salt thereof.

38. The compound according to claim 1, which is *N*-((3*S*,4*S*)-3-fluoropiperidin-4-yl)-2,2-dimethyl-3-((3-(trifluoromethyl)pyridin-2-yl)oxy)propanamide or a pharmaceutically acceptable salt thereof.

39. The compound according to claim 1, which is 3-(2-chlorophenoxy)-2,2-dimethyl-*N*-((3*S*,4*S*)-3-methylpiperidin-4-yl)propanamide or a pharmaceutically acceptable salt thereof.

40. The compound according to claim 1, which is 3-(2-fluorophenoxy)-2,2-dimethyl-*N*-((3*S*,4*S*)-3-methylpiperidin-4-yl)propanamide or a pharmaceutically acceptable salt thereof.

41. The compound according to claim 1, which is 3-((3-cyclopropylpyridin-2-yl)oxy)-2,2-difluoro-*N*-((3*S*,4*S*)-3-methylpiperidin-4-yl)propanamide or a pharmaceutically acceptable salt thereof.

42. The compound according to claim 1, which is 3-(2-chlorophenoxy)-2,2-dimethyl-*N*-(piperidin-4-yl)propanamide or a pharmaceutically acceptable salt thereof.

43. The compound according to claim 1, which is 3-(2-chlorophenoxy)-2,2-difluoro-*N*-((3*S*,4*S*)-3-methylpiperidin-4-yl)propanamide or a pharmaceutical acceptable salt thereof.

~~36~~44. A pharmaceutical composition comprising:

a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to ~~35~~43; and

a pharmaceutically acceptable excipient.

~~37~~45. A compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 35 for use as a medicament.

~~38~~46. A compound or pharmaceutically acceptable salt as defined in any one of claims 1 to ~~35~~43 for use in treatment of a disease, disorder or condition selected from Alzheimer's disease, depression, anxiety, schizophrenia, bipolar disorder, autism, epilepsy, pain, and hyperactivity disorder.

~~39~~47. Use of a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to ~~35~~43 in the manufacture of a medicament for treating a disease, disorder or condition in a subject, wherein the disease, disorder or condition is selected from Alzheimer's disease, depression, anxiety, schizophrenia, bipolar disorder, autism, epilepsy, pain, and hyperactivity disorder, and wherein said compound or pharmaceutically acceptable salt is to be administered to the subject.

~~40~~48. A combination comprising a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to ~~35~~43, and at least one additional pharmacologically active agent.

~~41~~49. The combination according to claim ~~40~~48, wherein the additional pharmacologically active agent is selected from beta-secretase inhibitors, gamma-secretase inhibitors, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs, vitamin E, anti-amyloid antibodies, antidepressants, antipsychotics, anxiolytics, and anticonvulsants.